The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

By B. Lynch, N. Lambeng, K. Nocka, Patricia Kensel-Hammes, S. Bajjalieh, A. Matagne, B. Fuks. Proceedings of the National Academy of Sciences of the United States of America, 2004

1,445 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/388e616bdcf4d79cffcdee535e4fd04863e96339

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. L. Mucke
2. J. Palop
3. Gui-qiu Yu
4. D. Holtzman

In Molecular Biology

1. L. Mucke
2. J. Palop

In Psychiatry and Mental health

1. L. Mucke
2. J. Palop

Citations in the corpus

• Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model (2012, background): “The antiepileptic efficacy of LEV appears to depend on its binding to the synaptic vesicle protein 2A (SV2A) (47).”